Electrocardiographic	electrocardiographic	O	O	O	O
changes	changes	O	O	O	O
and	and	O	O	O	O
cardiac	cardiac	O	DISEASE	OTHERS	I
arrhythmias	arrhythmias	O	DISEASE	OTHERS	I
in	in	O	O	O	O
patients	patients	O	O	O	O
receiving	receiving	O	O	O	O
psychotropic	psychotropic	CHEMICALS	O	OTHERS	I
drugs	drugs	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

Eight	eight	O	O	O	O
patients	patients	O	O	O	O
had	had	O	O	O	O
cardiac	cardiac	O	O	O	O
manifestations	manifestations	O	O	O	O
that	that	O	O	O	O
were	were	O	O	O	O
life-threatening	life-threatening	O	O	O	O
in	in	O	O	O	O
five	five	O	O	O	O
while	while	O	O	O	O
taking	taking	O	O	O	O
psychotropic	psychotropic	CHEMICALS	O	OTHERS	I
drugs	drugs	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
either	either	O	O	O	O
phenothiazines	phenothiazines	O	O	OTHERS	I
or	or	O	O	O	O
tricyclic	tricyclic	O	O	O	O
antidepressants	antidepressants	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

Although	although	O	O	O	O
most	most	O	O	O	O
patients	patients	O	O	O	O
were	were	O	O	O	O
receiving	receiving	O	O	O	O
several	several	O	O	O	O
drugs	drugs	O	O	O	O
,	,	O	O	O	O
Mellaril	mellaril	O	O	OTHERS	I
(	(	O	O	O	O
thioridazine	thioridazine	O	O	OTHERS	I
)	)	O	O	O	O
appeared	appeared	O	O	O	O
to	to	O	O	O	O
be	be	O	O	O	O
responsible	responsible	O	O	O	O
for	for	O	O	O	O
five	five	O	O	O	O
cases	cases	O	O	O	O
of	of	O	O	O	O
ventricular	ventricular	O	DISEASE	OTHERS	I
tachycardia	tachycardia	O	DISEASE	OTHERS	I
,	,	O	O	O	O
one	one	O	O	O	O
of	of	O	O	O	O
which	which	O	O	O	O
was	was	O	O	O	O
fatal	fatal	O	O	O	O
in	in	O	O	O	O
a	a	O	O	O	O
35	35	O	O	O	O
year	year	O	O	O	O
old	old	O	O	O	O
woman	woman	O	O	O	O
.	.	O	O	O	O

Supraventricular	supraventricular	O	O	OTHERS	I
tachycardia	tachycardia	O	DISEASE	OTHERS	I
developed	developed	O	O	O	O
in	in	O	O	O	O
one	one	O	O	O	O
patient	patient	O	O	O	O
receiving	receiving	O	O	O	O
Thorazine	thorazine	O	O	OTHERS	I
(	(	O	O	O	O
chlorpromazine	chlorpromazine	CHEMICALS	O	OTHERS	I
)	)	O	O	O	O
.	.	O	O	O	O

Aventyl	aventyl	O	O	OTHERS	I
(	(	O	O	O	O
nortriptyline	nortriptyline	O	O	OTHERS	I
)	)	O	O	O	O
and	and	O	O	O	O
Elavil	elavil	O	O	OTHERS	I
(	(	O	O	O	O
amitriptyline	amitriptyline	CHEMICALS	O	OTHERS	I
)	)	O	O	O	O
each	each	O	O	O	O
produced	produced	O	O	O	O
left	left	O	O	OTHERS	I
bundle	bundle	O	O	OTHERS	I
branch	branch	O	O	OTHERS	I
block	block	O	O	OTHERS	I
in	in	O	O	O	O
a	a	O	O	O	O
73	73	O	O	O	O
year	year	O	O	O	O
old	old	O	O	O	O
woman	woman	O	O	O	O
.	.	O	O	O	O

Electrocardiographic	electrocardiographic	O	O	O	O
T	t	O	O	O	O
and	and	O	O	O	O
U	u	O	O	O	O
wave	wave	O	O	O	O
abnormalities	abnormalities	O	O	O	O
were	were	O	O	O	O
present	present	O	O	O	O
in	in	O	O	O	O
most	most	O	O	O	O
patients	patients	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
ventricular	ventricular	O	DISEASE	OTHERS	I
arrhythmias	arrhythmias	O	DISEASE	OTHERS	I
responded	responded	O	O	O	O
to	to	O	O	O	O
intravenous	intravenous	O	O	O	O
administration	administration	O	O	O	O
of	of	O	O	O	O
lidocaine	lidocaine	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
to	to	O	O	O	O
direct	direct	O	O	O	O
current	current	O	O	O	O
electric	electric	O	O	O	O
shock	shock	O	DISEASE	OTHERS	I
;	;	O	O	O	O
ventricular	ventricular	O	O	O	O
pacing	pacing	O	O	O	O
was	was	O	O	O	O
required	required	O	O	O	O
in	in	O	O	O	O
some	some	O	O	O	O
instances	instances	O	O	O	O
and	and	O	O	O	O
intravenous	intravenous	O	O	O	O
administration	administration	O	O	O	O
of	of	O	O	O	O
propranolol	propranolol	CHEMICALS	O	OTHERS	I
combined	combined	O	O	O	O
with	with	O	O	O	O
ventricular	ventricular	O	O	O	O
pacing	pacing	O	O	O	O
in	in	O	O	O	O
one	one	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
tachyarrhythmias	tachyarrhythmias	O	O	OTHERS	I
generally	generally	O	O	O	O
subsided	subsided	O	O	O	O
within	within	O	O	O	O
48	48	O	O	O	O
hours	hours	O	O	O	O
after	after	O	O	O	O
administration	administration	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
drugs	drugs	O	O	O	O
was	was	O	O	O	O
stopped	stopped	O	O	O	O
.	.	O	O	O	O

Five	five	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
eight	eight	O	O	O	O
patients	patients	O	O	O	O
were	were	O	O	O	O
50	50	O	O	O	O
years	years	O	O	O	O
of	of	O	O	O	O
age	age	O	O	O	O
or	or	O	O	O	O
younger	younger	O	O	O	O
;	;	O	O	O	O
only	only	O	O	O	O
one	one	O	O	O	O
clearly	clearly	O	O	O	O
had	had	O	O	O	O
antecedent	antecedent	O	O	O	O
heart	heart	O	DISEASE	OTHERS	I
disease	disease	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Major	major	O	O	O	O
cardiac	cardiac	O	DISEASE	OTHERS	I
arrhythmias	arrhythmias	O	DISEASE	OTHERS	I
are	are	O	O	O	O
a	a	O	O	O	O
potential	potential	O	O	O	O
hazard	hazard	O	O	O	O
in	in	O	O	O	O
patients	patients	O	O	O	O
without	without	O	O	O	O
heart	heart	O	DISEASE	OTHERS	I
disease	disease	O	DISEASE	OTHERS	I
who	who	O	O	O	O
are	are	O	O	O	O
receiving	receiving	O	O	O	O
customary	customary	O	O	O	O
therapeutic	therapeutic	O	O	O	O
doses	doses	O	O	O	O
of	of	O	O	O	O
psychotropic	psychotropic	CHEMICALS	O	OTHERS	I
drugs	drugs	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

A	a	O	O	O	O
prospective	prospective	O	O	O	O
clinical	clinical	O	O	O	O
trial	trial	O	O	O	O
is	is	O	O	O	O
suggested	suggested	O	O	O	O
to	to	O	O	O	O
quantify	quantify	O	O	O	O
the	the	O	O	O	O
risk	risk	O	O	O	O
of	of	O	O	O	O
cardiac	cardiac	O	O	OTHERS	I
complications	complications	O	O	OTHERS	I
to	to	O	O	O	O
patients	patients	O	O	O	O
receiving	receiving	O	O	O	O
phenothiazines	phenothiazines	O	O	OTHERS	I
or	or	O	O	O	O
tricyclic	tricyclic	O	O	O	O
antidepressant	antidepressant	CHEMICALS	O	OTHERS	I
drugs	drugs	O	O	O	O
.	.	O	O	O	O

